Healthcare / Diagnostics & Research
Exclusive insider sentiment analysis for the Diagnostics & Research sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-22 20:05 | 2026-07-20 | RVTY | REVVITY, INC. | Gonzales Anita | Officer; Vice President and CAO | Diagnostics & Research | SALE | $109.48 | 85 | $9,306 | 7,201 | -1.2% |
| 2026-07-20 23:38 | 2026-07-16 | BLLN | BillionToOne, Inc. | Johnson Nancy JoAnn | Officer; See Remarks | Diagnostics & Research | SALE | $128.29 | 14,199 | $1,821,628 | 6,900 | -67.3% |
| 2026-07-18 01:05 | 2026-07-15 | NTRA | Natera, Inc. | Chapman Rowan E | Director | Diagnostics & Research | SALE | $274.82 | 135 | $37,101 | 4,663 | -2.8% |
| 2026-07-18 01:05 | 2026-07-15 | NTRA | Natera, Inc. | Sheena Jonathan | Director, Other | Diagnostics & Research | SALE | $273.88 | 1,500 | $410,825 | 18,032 | -7.7% |
| 2026-07-17 20:22 | 2026-07-16 | CDNA | CareDx, Inc. | Valantine Hannah | Director | Diagnostics & Research | OPT+S | $36.15 | 28,779 | $1,040,243 | 36,686 | -44.0% |
| 2026-07-17 20:23 | 2026-07-16 | CDNA | CareDx, Inc. | Hanna John Walter JR | Director, Officer; President and CEO | Diagnostics & Research | OPT+S | $37.79 | 118,000 | $4,458,642 | 653,448 | -15.3% |
| 2026-07-16 20:56 | 2026-07-16 | GH | Guardant Health, Inc. | Tariq Musa | Director | Diagnostics & Research | OPT+S | $163.29 | 116 | $18,942 | 11,182 | -1.0% |
| 2026-07-16 20:16 | 2026-07-14 | CSTL | CASTLE BIOSCIENCES INC | MAETZOLD DEREK J | Director, Officer; Pres. & Chief Exec. Officer | Diagnostics & Research | OPT+S | $22.92 | 4,172 | $95,622 | 12,090 | -25.7% |
| 2026-07-16 01:27 | 2026-07-15 | PSNL | Personalis, Inc. | Chen Richard | Officer; President and CMO | Diagnostics & Research | OPT+S | $15.15 | 100,000 | $1,515,000 | 173,880 | -36.5% |
| 2026-07-16 01:05 | 2026-07-13 | NTRA | Natera, Inc. | Sheena Jonathan | Director, Other | Diagnostics & Research | SALE | $265.68 | 3,150 | $836,898 | 246,202 | -1.3% |
| 2026-07-15 20:38 | 2026-07-13 | BLLN | BillionToOne, Inc. | Tsao David | Director, Officer; Chief Technology Officer | Diagnostics & Research | OPT+S | $124.88 | 20,000 | $2,497,698 | 1,000 | -95.2% |
| 2026-07-15 20:38 | 2026-07-13 | BLLN | BillionToOne, Inc. | ten Bosch John Roderick | Officer; SVP of Laboratory Operations | Diagnostics & Research | SALE | $125.46 | 4,251 | $533,330 | 29,301 | -12.7% |
| 2026-07-13 20:39 | 2026-07-09 | BLLN | BillionToOne, Inc. | Sakakibara Shan Riku | Officer; Chief Product Officer | Diagnostics & Research | OPT+S | $125.00 | 8,000 | $1,000,000 | 204,000 | -3.8% |
| 2026-07-13 20:39 | 2026-07-09 | BLLN | BillionToOne, Inc. | Atay Oguzhan | Director, Officer; Chairman and CEO | Diagnostics & Research | OPT+S | $126.10 | 12,500 | $1,576,276 | 0 | -100.0% |
| 2026-07-13 20:05 | 2026-07-09 | TWST | Twist Bioscience Corp | Laponis Adam | Officer; Chief Financial Officer | Diagnostics & Research | SALE | $94.33 | 2,399 | $226,307 | 110,276 | -2.1% |
| 2026-07-10 00:46 | 2026-07-09 | PSNL | Personalis, Inc. | Hall Christopher M | Director, Officer; Chief Executive Officer | Diagnostics & Research | OPT+S | $15.08 | 100,000 | $1,508,000 | 235,986 | -29.8% |
| 2026-07-08 23:06 | 2026-07-06 | BLLN | BillionToOne, Inc. | Atay Oguzhan | Director, Officer; Chairman and CEO | Diagnostics & Research | OPT+S | $122.05 | 38,750 | $4,729,379 | 175,000 | -18.1% |
| 2026-07-09 01:05 | 2026-07-06 | NTRA | Natera, Inc. | Rabinowitz Matthew | Director, Officer; EXECUTIVE CHAIRMAN | Diagnostics & Research | SALE | $280.00 | 1,000 | $280,000 | 4,000 | -20.0% |
| 2026-07-06 20:24 | 2026-07-01 | CSTL | CASTLE BIOSCIENCES INC | Oelschlager Kristen M | Officer; Chief Operating Officer | Diagnostics & Research | SALE | $24.42 | 8,586 | $209,650 | 21,874 | -28.2% |
| 2026-07-06 20:25 | 2026-07-01 | CSTL | CASTLE BIOSCIENCES INC | MAETZOLD DEREK J | Director, Officer; Pres. & Chief Exec. Officer | Diagnostics & Research | OPT+S | $24.29 | 9,836 | $238,916 | 12,368 | -44.3% |
| 2026-07-07 01:05 | 2026-07-01 | NTRA | Natera, Inc. | Moshkevich Solomon | Officer; PRESIDENT, CLINICALDIAGNOSTICS | Diagnostics & Research | SALE | $272.90 | 3,000 | $818,711 | 134,643 | -2.2% |
| 2026-07-07 01:05 | 2026-07-01 | NTRA | Natera, Inc. | RABINOWITZ DANIEL | Officer; SEC. AND CHIEF LEGAL OFFICER | Diagnostics & Research | SALE | $272.29 | 16,800 | $4,574,430 | 172,294 | -8.9% |
| 2026-07-07 00:38 | 2026-07-01 | BLLN | BillionToOne, Inc. | Johnson Nancy JoAnn | Officer; See Remarks | Diagnostics & Research | SALE | $124.91 | 801 | $100,056 | 21,099 | -3.7% |
| 2026-07-06 13:36 | 2026-07-02 | LH | LABCORP HOLDINGS INC. | Vaughn Bryan T | Officer; EVP and President, Diagnostics | Diagnostics & Research | OPT+S | $286.19 | 234 | $66,968 | 6,746 | -3.4% |
| 2026-07-06 13:37 | 2026-07-02 | LH | LABCORP HOLDINGS INC. | Kyle Kathryn W | Officer; EVP, Chief Legal Officer | Diagnostics & Research | OPT+S | $286.19 | 92 | $26,329 | 3,904 | -2.3% |
| 2026-07-02 12:30 | 2026-06-11 | BNR | Burning Rock Biotech Ltd | Han Yusheng | Director | Diagnostics & Research | BUY | $8.45 | 731,410 | $6,182,170 | 18,404,086 | +4.1% |
| 2026-07-01 20:23 | 2026-06-29 | BLLN | BillionToOne, Inc. | ten Bosch John Roderick | Officer; SVP of Laboratory Operations | Diagnostics & Research | SALE | $120.00 | 1,416 | $169,920 | 33,552 | -4.0% |
| 2026-07-01 20:59 | 2026-06-29 | CRL | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. | FOSTER JAMES C | Director | Diagnostics & Research | SALE | $225.00 | 75,000 | $16,875,000 | 31,596 | -70.4% |
| 2026-06-30 21:40 | 2026-06-15 | GH | Guardant Health, Inc. | Kalia Kumud | Officer; Chief Information Officer | Diagnostics & Research | BUY | $130.76 | 600 | $78,456 | 41,414 | +1.5% |
| 2026-06-30 21:40 | 2026-06-10 | GH | Guardant Health, Inc. | Kalia Kumud | Officer; Chief Information Officer | Diagnostics & Research | SALE | $130.97 | 1,200 | $157,164 | 40,814 | -2.9% |
| 2026-06-30 21:29 | 2026-06-26 | CDNA | CareDx, Inc. | Hanna John Walter JR | Director, Officer; President and CEO | Diagnostics & Research | OPT+S | $29.24 | 40,000 | $1,169,736 | 661,959 | -5.7% |
| 2026-06-30 21:13 | 2026-06-26 | GH | Guardant Health, Inc. | Talasaz AmirAli | Director, Officer; Co-Chief Executive Officer | Diagnostics & Research | OPT+S | $151.20 | 260,000 | $39,312,650 | 1,881,336 | -12.1% |
| 2026-06-29 21:50 | 2026-06-29 | PSNL | Personalis, Inc. | Tachibana Aaron | Officer; CFO AND COO | Diagnostics & Research | OPT+S | $14.00 | 4,982 | $69,748 | 198,833 | -2.4% |
| 2026-06-26 20:05 | 2026-06-24 | TWST | Twist Bioscience Corp | Cho Dennis | Officer; See Remarks | Diagnostics & Research | SALE | $89.75 | 14,205 | $1,274,899 | 105,141 | -11.9% |
| 2026-06-27 01:05 | 2026-06-24 | NTRA | Natera, Inc. | ROSENMAN HERM | Director | Diagnostics & Research | SALE | $250.00 | 16,530 | $4,132,500 | 4,250 | -79.5% |
| 2026-06-27 01:05 | 2026-06-24 | NTRA | Natera, Inc. | RABINOWITZ DANIEL | Officer; SEC. AND CHIEF LEGAL OFFICER | Diagnostics & Research | SALE | $251.65 | 33,600 | $8,455,356 | 189,094 | -15.1% |
| 2026-06-26 23:56 | 2026-06-26 | PSNL | Personalis, Inc. | Tachibana Aaron | Officer; CFO AND COO | Diagnostics & Research | OPT+S | $13.18 | 51,251 | $675,488 | 198,833 | -20.5% |
| 2026-06-26 23:49 | 2026-06-26 | PSNL | Personalis, Inc. | Hall Christopher M | Director, Officer; Chief Executive Officer | Diagnostics & Research | OPT+S | $13.15 | 100,000 | $1,315,000 | 235,986 | -29.8% |
| 2026-06-26 21:20 | 2026-06-24 | BLLN | BillionToOne, Inc. | Sakakibara Shan Riku | Officer; Chief Product Officer | Diagnostics & Research | OPT+S | $110.00 | 8,000 | $880,000 | 208,000 | -3.7% |
| 2026-06-26 20:41 | 2026-06-25 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer; Chief Executive Officer | Diagnostics & Research | SALE | $95.00 | 18,880 | $1,793,600 | 824,039 | -2.2% |
| 2026-06-26 01:41 | 2026-06-25 | ILMN | ILLUMINA, INC. | Davies Scott M | Officer; Chief Legal Officer | Diagnostics & Research | SALE | $180.00 | 615 | $110,700 | 20,953 | -2.9% |
| 2026-06-24 20:05 | 2026-06-22 | TWST | Twist Bioscience Corp | Green Paula | Officer; SVP of Human Resources | Diagnostics & Research | SALE | $87.32 | 291 | $25,411 | 120,414 | -0.2% |
| 2026-06-24 20:05 | 2026-06-22 | TWST | Twist Bioscience Corp | Leproust Emily M. | Director, Officer; Chief Executive Officer | Diagnostics & Research | SALE | $87.32 | 1,688 | $147,400 | 842,919 | -0.2% |
| 2026-06-24 20:05 | 2026-06-22 | TWST | Twist Bioscience Corp | Cho Dennis | Officer; See Remarks | Diagnostics & Research | SALE | $87.32 | 346 | $30,214 | 119,346 | -0.3% |
| 2026-06-23 21:28 | 2026-06-22 | GH | Guardant Health, Inc. | POTTER MYRTLE S | Director | Diagnostics & Research | SALE | $131.16 | 1,556 | $204,085 | 20,971 | -6.9% |
| 2026-06-23 21:29 | 2026-06-22 | GH | Guardant Health, Inc. | Tariq Musa | Director | Diagnostics & Research | SALE | $131.16 | 1,951 | $255,893 | 11,048 | -15.0% |
| 2026-06-23 01:05 | 2026-06-17 | NTRA | Natera, Inc. | Sheena Jonathan | Director, Other | Diagnostics & Research | SALE | $219.87 | 1,500 | $329,810 | 18,782 | -7.4% |
| 2026-06-22 20:30 | 2026-06-18 | VCYT | VERACYTE, INC. | EASTHAM KARIN | Director | Diagnostics & Research | SALE | $52.89 | 3,729 | $197,234 | 15,097 | -19.8% |
| 2026-06-22 20:15 | 2026-06-18 | RDNT | RadNet, Inc. | SWARTZ DAVID L | Director | Diagnostics & Research | SALE | $53.89 | 2,699 | $145,449 | 177,013 | -1.5% |
| 2026-06-18 20:11 | 2026-06-16 | WGS | GeneDx Holdings Corp. | Feeley Kevin | Officer; CHIEF FINANCIAL OFFICER | Diagnostics & Research | OPT+S | $60.77 | 3,729 | $226,597 | 39,954 | -8.5% |
Strategic Analysis
Analyzing insider transactions within the Diagnostics & Research sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.